For how we live.
In 108 people with Parkinson's, diffusion MRI found that damage to cholinergic pathways running from a deep-brain nucleus tracked worse cognition — and was most marked in those with dementia.
Among 287 people with REM sleep behaviour disorder followed about four years, 15.7% developed a synucleinopathy. Higher coffee intake was linked to a lower risk of progression.
AbbVie's once-daily pill cleared the FDA on 25 September as a new molecular entity. Across three phase 3 TEMPO trials it beat placebo in early Parkinson's and as an add-on to levodopa.
A single-centre, placebo-controlled trial found targeted onabotulinumtoxinA injections cut dystonia-related foot pain without harming movement. The effect was large, but the trial randomised only 33 people.
A fine tremor everyone has — worsened by caffeine, stress, tiredness or some drugs — is the usual cause. Essential tremor is the commonest tremor disorder; a shake at rest is the one that points elsewhere.
Physically acting out dreams is one of the strongest known early signs of Parkinson's and related diseases. In a 1,280-patient cohort, most converted within 12 years — but it is a risk marker, not a verdict.
In half a million Chinese adults, higher exhaled carbon monoxide tracked with lower Parkinson's risk even among people who never smoked. It is an association, not a therapy.
Stanford's SleepFM, published in Nature Medicine in January 2026, is the most consequential sleep paper of the year. Its own limitations section explains why it is not yet a clinical test.
A once-daily experimental pill beat placebo in a phase 3 trial and is under regulatory review — yet no study has tested its claimed edge over older dopamine agonists head-to-head.
The anti-alpha-synuclein antibody did not significantly delay motor progression in the phase 2b PADOVA study, though a non-significant trend and secondary signals keep a phase 3 trial alive.
Pooling 94 cohort studies, grip strength tracked with later dementia, depression and disability. The authors rate their own confidence in the numbers as limited to moderate.
A 220,000-person cohort found opposite associations for two neurodegenerative diseases depending on the type and distance of greenery. Two other February papers ask who can actually use it.